Literature DB >> 30416618

Critical exacerbation of idiopathic pulmonary fibrosis after transcatheter aortic valve implantation: Need for multidisciplinary care beyond "heart team".

Yoichiro Sugizaki1, Shumpei Mori1, Yuichi Nagamatsu1, Tomomi Akita1, Akira Nagasawa1, Takayoshi Toba1, Masatsugu Yamamoto2, Tatsuya Nishii3, Norihiko Obata4, Yoshikatsu Nomura5, Hiromasa Otake1, Toshiro Shinke1, Yutaka Okita5, Ken-Ichi Hirata1.   

Abstract

An 82-year-old man with severe aortic stenosis and idiopathic pulmonary fibrosis (IPF) underwent transcatheter aortic valve implantation (TAVI) under general anesthesia. However, following a successful TAVI procedure, he developed progressive respiratory failure because of the exacerbation of IPF. Despite the use of immunosuppressants, the patient could not be saved and he died of respiratory failure. Although TAVI is a less invasive procedure compared to conventional surgical aortic valve replacement, it is currently selected for management of severely ill, frail, and elderly patients. This case highlights the potential risk of IPF exacerbation following a TAVI procedure performed under general anesthesia. <Learning objective: Transcatheter aortic valve implantation (TAVI) procedures have been increasingly performed for high-risk patients, including those with high frailty and pulmonary dysfunction. Although TAVI is less invasive compared to open surgery, it may cause critical exacerbation of idiopathic pulmonary fibrosis when performed under general anesthesia. Multidisciplinary care beyond "heart team" would be necessary for prevention, as well as for detecting the early signs of exacerbation of idiopathic pulmonary fibrosis.>.

Entities:  

Keywords:  Aortic stenosis; General anesthesia; Idiopathic pulmonary fibrosis; Transcatheter aortic valve implantation

Year:  2018        PMID: 30416618      PMCID: PMC6218371          DOI: 10.1016/j.jccase.2018.07.005

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  13 in total

1.  Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases.

Authors:  Hiroshi Ohnishi; Akihito Yokoyama; Keiichi Kondo; Hironobu Hamada; Masahiro Abe; Kazutaka Nishimura; Kunio Hiwada; Nobuoki Kohno
Journal:  Am J Respir Crit Care Med       Date:  2002-02-01       Impact factor: 21.405

2.  Transcatheter versus surgical aortic-valve replacement in high-risk patients.

Authors:  Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

3.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

4.  Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: correlation with physiological parameters.

Authors:  D Papakosta; G Pitsiou; Z Daniil; M Dimadi; E Stagaki; A Rapti; K Antoniou; A Tzouvelekis; T Kontakiotis; S Tryfon; V Polychronopoulos; D Bouros
Journal:  Lung       Date:  2011-06-11       Impact factor: 2.584

5.  The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer.

Authors:  Yoshimasa Mizuno; Hisashi Iwata; Koyo Shirahashi; Kazuya Takamochi; Shiaki Oh; Kenji Suzuki; Hirofumi Takemura
Journal:  Eur J Cardiothorac Surg       Date:  2012-04-14       Impact factor: 4.191

Review 6.  Exacerbations in idiopathic pulmonary fibrosis triggered by pulmonary and nonpulmonary surgery: a case series and comprehensive review of the literature.

Authors:  Abhijeet Ghatol; A Parker Ruhl; Sonye K Danoff
Journal:  Lung       Date:  2012-04-29       Impact factor: 2.584

7.  Acute exacerbation of idiopathic interstitial pneumonia following lung surgery in 3 of 68 consecutive patients: a retrospective study.

Authors:  Susumu Sakamoto; Sakae Homma; Mingyon Mun; Takeshi Fujii; Atsuko Kurosaki; Kunihiko Yoshimura
Journal:  Intern Med       Date:  2011-01-15       Impact factor: 1.271

8.  Postoperative pulmonary complications after surgery in patients with interstitial lung disease.

Authors:  Sun Mi Choi; Jinwoo Lee; Young Sik Park; Young-Jae Cho; Chang-Hoon Lee; Sang-Min Lee; Ho Il Yoon; Jae-Joon Yim; Jae Ho Lee; Chul-Gyu Yoo; Choon-Taek Lee; Young Whan Kim; Jong Sun Park
Journal:  Respiration       Date:  2014-02-21       Impact factor: 3.580

9.  Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis.

Authors:  Takekazu Iwata; Shigetoshi Yoshida; Taiki Fujiwara; Hironobu Wada; Takahiro Nakajima; Hidemi Suzuki; Ichiro Yoshino
Journal:  Ann Thorac Surg       Date:  2016-08-18       Impact factor: 4.330

10.  Interstitial lung abnormality is prevalent and associated with worse outcome in patients undergoing transcatheter aortic valve replacement.

Authors:  Michael Kadoch; Aleksandar Kitich; Shehabaldin Alqalyoobi; Elyse Lafond; Elena Foster; Maya Juarez; Cesar Mendez; Thomas W Smith; Garrett Wong; Walter D Boyd; Jeffrey Southard; Justin M Oldham
Journal:  Respir Med       Date:  2018-02-27       Impact factor: 3.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.